Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2022
Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...
Posted by Michael Wonder on 05 Oct 2022
Ozanimod hydrochloride for treating moderate to severe active ulcerative colitis
5 October 2022 - NICE has published evidence based recommendations on the use of ozanimod hydrochloride for the treatment of ...
Posted by Michael Wonder on 05 Oct 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
5 October 2022 - NICE has published evidence based recommendations on the use of azacitidine for the maintenance treatment of ...
Posted by Michael Wonder on 05 Oct 2022
New PHARMAC funded drug will help in the cancer battle - but it's still not enough
5 October 2022 - Lung Foundation New Zealand CEO Philip Hope says funding by PHARMAC of a new cancer drug is ...
Posted by Michael Wonder on 04 Oct 2022
Landmark PBS listing for treatment of gastro-oesophageal cancers
1 October 2022 - From 1 October, Australians with advanced or metastatic gastro-oesophageal cancers will have access to new treatment through ...
Posted by Michael Wonder on 04 Oct 2022
2022 October price disclosure cycle – confirmed prices and patient savings reports
1 October 2022 - Combination flow-on reduction outcomes reflect confirmed 1 October 2022 prices on the Current Price Disclosure cycle web ...
Posted by Michael Wonder on 03 Oct 2022
New Zealand Pharmaceutical Schedule - 1 October 2022
1 October 2022 - The October 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 03 Oct 2022
‘Underlying guilt’ turns to delight after PHARMAC decision
30 September 2022 - Lani McLeod has had an underlying feeling of guilt for two years that her boys had ...
Posted by Michael Wonder on 30 Sep 2022
Schedule of Pharmaceutical Benefits - 1 October 2022
1 October 2022 - The October 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Sep 2022
NICE review does not recommend routine funding for Duchenne muscular dystrophy gene therapy ataluren in draft guidance
30 September 2022 - NICE has today published draft guidance for public consultation which does not recommend ataluren (Translarna, PTC Therapeutics) ...
Posted by Michael Wonder on 29 Sep 2022
Why non-funding of cystic fibrosis treatment is unacceptable
30 September 2022 - Edward Lee has self-funded the Trikafta drug that alleviates the symptoms of his cystic fibrosis since 2019. ...
Posted by Michael Wonder on 29 Sep 2022
Auckland toddler may be able to dance again after PHARMAC proposes funding drug
29 September 2022 - An Auckland toddler who was losing the ability to walk may be able to dance again, ...
Posted by Michael Wonder on 28 Sep 2022
News “hyperbole” in Government media releases on new drugs can undermine confidence in NHS, says editor
28 September 2022 - Phrases such as “cutting edge,” “game changing,” and “ground breaking” have no place in the description ...
Posted by Michael Wonder on 28 Sep 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
28 September 2022 - NICE has published evidence-based recommendations on the use of atezolizumab for adjuvant treatment of adults with ...
Posted by Michael Wonder on 27 Sep 2022
More medicines for New Zealanders, thanks to Government’s Budget boost
28 September 2022 - Health Minister Andrew Little is welcoming news that two more important medicines are set to be ...